<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02945527</url>
  </required_header>
  <id_info>
    <org_study_id>62352</org_study_id>
    <nct_id>NCT02945527</nct_id>
  </id_info>
  <brief_title>Treatment of Peri-calcification Edema in Neurocysticercosis (NCC)</brief_title>
  <official_title>Open Controled Randomized Pilot Study on the Use of Acetazolamide and Dexamethasone for the Acute Phase of Perilesional Edema in Calcified Neurocysticercosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Peruana Cayetano Heredia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad Peruana Cayetano Heredia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Three-arm open, randomized comparative study of acetazolamide, dexamethasone, or no
      additional treatment to evaluate decrease in peri-calcification edema in neurocysticercosis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate 24 patients with calcified NCC and edema in three treatment arms to
      compare the reduction in edema volume
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in Volume of Perilesional Edema Between Baseline and Day 4</measure>
    <time_frame>Baseline to Day 4</time_frame>
    <description>MRI extension of edema</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease in Volume of Perilesional Edema Between Baseline and Day 8</measure>
    <time_frame>Baseline to Day 8</time_frame>
    <description>MRI extension of edema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in Volume of Perilesional Edema Between Baseline and Day 30</measure>
    <time_frame>Baseline to Day 30</time_frame>
    <description>MRI extension of edema</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Neurocysticercosis</condition>
  <arm_group>
    <arm_group_label>Acetazolamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>750 mg acetazolamide p.o. divided in three dily doses, for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8 mg p.o. divided in three daily daily doses, for 2 days followed by gradual tapering</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No additional anti-edema treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No additional treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetazolamide</intervention_name>
    <description>As described above</description>
    <arm_group_label>Acetazolamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>As described above</description>
    <arm_group_label>Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Calcified NCC

          -  Perilesional edema on CT or MRI

          -  Normal lab values

        Exclusion Criteria:

          -  Viable neurocysticercosis

          -  Status epilepticus

          -  Symptomatic intracranial hypertension

          -  Tuberculosis

          -  More than 7 days after seizure

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hector H. Garcia, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Universidad Peruana Cayetano Heredia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hector H Garcia, MD, PhD</last_name>
    <phone>+511 3287360</phone>
    <email>hector.garcia@upch.pe</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Javier Bustos, MD, MPH</last_name>
    <phone>+511 3284038</phone>
    <email>jbustos@jhsph.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cysticercosis Unit, Instituto Nacional de Ciencias Neurologicas</name>
      <address>
        <city>Lima</city>
        <zip>Lima 1</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isidro Gonzales, MD</last_name>
      <phone>+511 3288589</phone>
      <email>isidrogonzalesq@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Peru</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2016</study_first_submitted>
  <study_first_submitted_qc>October 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2016</study_first_posted>
  <last_update_submitted>October 26, 2017</last_update_submitted>
  <last_update_submitted_qc>October 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurocysticercosis</mesh_term>
    <mesh_term>Cysticercosis</mesh_term>
    <mesh_term>Taeniasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Acetazolamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>As a concrete product, the clinical trial should provide base data to implement an affordable therapy for edema-related seizures. The data produced will be published in a peer reviewed journal.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

